Rafferty Asset Management, LLC

Position in KALV — KalVista Pharmaceuticals, Inc.

CIK 1389426 New York, NY

Position in KALV

as of Mar 31, 2026 · filed May 15, 2026 Compact

Position Value

$1,153,368

+$94,042 QoQ

Shares Held

57,296

-12.6% QoQ

Ownership

0.108%

of shares outstanding

% of Portfolio

0.01%

of 13F equity value

Holder Rank

#72

of 182 holders

Holding Since

Mar 2021

12 quarters on record

Voting authority Sole 100.ToString("F0")% Shared 0.ToString("F0")% None 0.ToString("F0")%

Healthcare · as of Mar 31, 2026

Rafferty Asset Management, LLC holds $408,627,656 across 136 Biotechnology names. KALV ranks #91 (0.3% of the industry book) .

#	Ticker	Company	Shares	Value (USD)
1	VRTX	Vertex Pharmaceuticals Inc / Ma	54,572	$24,368,580
2	REGN	Regeneron Pharmaceuticals, Inc.	29,589	$22,861,644
3	INSM	INSMED Inc	116,069	$18,979,602
4	ALNY	Alnylam Pharmaceuticals, Inc.	50,553	$16,726,471
5	APLS	Apellis Pharmaceuticals, Inc.	180,471	$7,260,348
6	MRNA	Moderna, Inc.	114,194	$5,801,055
7	INCY	Incyte Corp	60,565	$5,700,377
8	MDGL	Madrigal Pharmaceuticals, Inc.	10,452	$5,471,308

12 filing rows on record

Report Date	Value (USD)	Shares	Change	Type	Discretion	Filed
2026-03-31	$1,153,368	57,296	-12.6%	Shares	Sole	2026-05-15
2025-12-31	$1,059,326	65,593	+13.5%	Shares	Sole	2026-02-13
2025-09-30	$703,882	57,790	+23.2%	Shares	Sole	2025-11-12
2025-06-30	$530,215	46,901	+78.5%	Shares	Sole	2025-08-14
2025-03-31	$303,144	26,269	-51.8%	Shares	Sole	2025-05-14
2024-12-31	$461,327	54,466	+24.3%	Shares	Sole	2025-02-14
2024-09-30	$507,551	43,830	-7.8%	Shares	Sole	2024-11-13
2022-03-31	$700,872	47,549	-25.9%	Shares	Sole	2022-05-13
2021-12-31	$849,180	64,186	+66.3%	Shares	Sole	2022-02-10
2021-09-30	$673,570	38,600	-35.4%	Shares	Sole	2021-11-10
2021-06-30	$1,430,987	59,724	+226.4%	Shares	Sole	2021-08-10
2021-03-31	$470,101	18,299	—	Shares	Sole	2021-05-10
No filing history on record for this holder in this stock.